Identification

Name
Prochlorperazine
Accession Number
DB00433  (APRD00624)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Structure
Thumb
Synonyms
  • 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
  • 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
  • 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
  • 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
  • Capazine
  • Chlormeprazine
  • Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
  • Chloropernazine
  • Emetiral
  • N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
  • Prochlorperazin
  • Prochlorpérazine
  • Prochlorperazinum
  • Prochlorpermazine
  • Prochlorpromazine
  • Procloperazine
  • Proclorperazina
External IDs
Bayer A 173 / RP 6140 / SKF 4657
Product Ingredients
IngredientUNIICASInChI Key
Prochlorperazine dimaleateNot AvailableNot AvailableNot applicable
Prochlorperazine edisylatePG20W5VQZS1257-78-9SWOUGRBFXFILIB-UHFFFAOYSA-N
Prochlorperazine maleateI1T8O1JTL684-02-6DSKIOWHQLUWFLG-SPIKMXEPSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nu-prochlor Tab 10mgTablet10 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prochlor Tab 5mgTablet5 mgOralNu Pharm Inc1992-12-312012-09-04Canada
PMS Prochlorperazine Inj 5mg/mlSolution5 mgIntramuscular; IntravenousPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Suppositoires 10mgSuppository10 mgRectalPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 10mgTablet10 mgOralPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 5mgTablet5 mgOralPharmascience Inc1989-12-31Not applicableCanada
ProchlorazineTablet10 mgOralAa Pharma Inc2000-02-09Not applicableCanada
ProchlorazineTablet5 mgOralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorperazine Mesylate Inj 5mg/mlLiquid5 mgIntramuscular; IntravenousSandoz Canada Incorporated1989-12-31Not applicableCanada
Sandoz ProchlorperazineSuppository10 mgRectalSandoz Canada Incorporated1989-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CompazineTablet, film coated5 mg/1OralPbm Pharmaceuticals Inc.2014-04-012016-01-27Us
CompazineTablet, film coated10 mg/1OralPbm Pharmaceuticals Inc.2014-04-012016-01-31Us
CompazineSuppository25 mg/1RectalPbm Pharmaceuticals Inc.2013-07-01Not applicableUs
ComproSuppository25 mg/1RectalPd Rx Pharmaceuticals, Inc.2000-09-01Not applicableUs
ComproSuppository25 mg/1RectalPaddock Laboratories, Inc.2000-09-01Not applicableUs
ComproSuppository25 mg/1RectalA S Medication Solutions2000-09-012017-06-20Us
ProchlorperazineSuppository25 mg/1RectalA S Medication Solutions1993-11-302017-06-20Us
ProchlorperazineSuppository25 mg/1RectalNucare Pharmaceuticals, Inc.1993-11-30Not applicableUs
ProchlorperazineSuppository25 mg/1RectalPhysicians Total Care, Inc.2001-07-20Not applicableUs
ProchlorperazineTablet10 mg/1OralStat Rx USA2009-07-29Not applicableUs00093 9652 01 nlmimage10 cf21678b
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prochlorperazine MaleateTablet, film coated5 mg/1OralDirectrx2017-01-01Not applicableUs
International/Other Brands
Buccastem (Reckitt Benckiser) / Emetiral (Zentiva) / Stemzine (Sanofi-Aventis) / Volimin (Chin Teng)
Categories
UNII
YHP6YLT61T
CAS number
58-38-8
Weight
Average: 373.943
Monoisotopic: 373.13794618
Chemical Formula
C20H24ClN3S
InChI Key
WIKYUJGCLQQFNW-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Pharmacology

Indication

For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.

Structured Indications
Pharmacodynamics

Prochlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics.

Mechanism of action

The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
Absorption

Rapidly absorbed following oral administration

Volume of distribution
Not Available
Protein binding

91-99%

Metabolism

Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4.

Route of elimination
Not Available
Half life

6 to 8 hours

Clearance
Not Available
Toxicity

Symptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus; LD50=400mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineProchlorperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineProchlorperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineProchlorperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Prochlorperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Prochlorperazine can be increased when it is combined with Abiraterone.Approved
AcebutololProchlorperazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Allopregnanolone.Investigational
AlmagateAlmagate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.Approved, Illicit, Investigational
AlprenololProchlorperazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Amantadine.Approved
AmiodaroneThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Prochlorperazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amperozide.Experimental
AmphetamineProchlorperazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.Approved, Investigational
ArotinololProchlorperazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Prochlorperazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Prochlorperazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Prochlorperazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Prochlorperazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Asenapine.Approved
AtazanavirThe metabolism of Prochlorperazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololProchlorperazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Prochlorperazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Prochlorperazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Azaperone.Investigational, Vet Approved
AzelastineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.Illicit
BefunololProchlorperazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzocaine.Approved
BenzphetamineProchlorperazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineProchlorperazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Prochlorperazine.Approved
BetaxololThe metabolism of Prochlorperazine can be decreased when combined with Betaxolol.Approved
BevantololProchlorperazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideProchlorperazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololProchlorperazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe metabolism of Prochlorperazine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololProchlorperazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Prochlorperazine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololProchlorperazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolProchlorperazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bupivacaine.Approved, Investigational
BupranololProchlorperazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Prochlorperazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Prochlorperazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.Approved
CarteololProchlorperazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolProchlorperazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Prochlorperazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololProchlorperazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Prochlorperazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine.Approved
ChlorphentermineProchlorperazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Prochlorperazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Prochlorperazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Prochlorperazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Prochlorperazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Prochlorperazine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Prochlorperazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.Approved
ClobazamThe metabolism of Prochlorperazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Prochlorperazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clopenthixol.Experimental
CloranololProchlorperazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Prochlorperazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Prochlorperazine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Prochlorperazine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Prochlorperazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.Approved, Illicit
ConivaptanThe serum concentration of Prochlorperazine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Prochlorperazine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.Approved
Cycloguanil embonateThe serum concentration of Prochlorperazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclosporineThe metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Prochlorperazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Prochlorperazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Prochlorperazine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeferoxamineThe risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.Approved, Investigational
DelavirdineThe metabolism of Prochlorperazine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.Approved
DesipramineThe metabolism of Prochlorperazine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineProchlorperazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diethyl ether.Experimental
DiethylpropionProchlorperazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Prochlorperazine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Prochlorperazine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Prochlorperazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dixyrazine.Experimental
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Prochlorperazine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Prochlorperazine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Prochlorperazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Illicit
DronedaroneThe metabolism of Prochlorperazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Prochlorperazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.Approved, Investigational
EliglustatThe metabolism of Prochlorperazine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.Approved
EpanololProchlorperazine may increase the hypotensive activities of Epanolol.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.Approved
ErythromycinThe metabolism of Prochlorperazine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.Approved, Investigational
EsmololProchlorperazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.Approved
EthanolProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Prochlorperazine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Prochlorperazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Prochlorperazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prochlorperazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Prochlorperazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.Approved, Investigational
Fusidic AcidThe serum concentration of Prochlorperazine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineProchlorperazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Prochlorperazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe metabolism of Prochlorperazine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prochlorperazine.Approved, Investigational
HydrocodoneProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineProchlorperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Prochlorperazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
IdelalisibThe serum concentration of Prochlorperazine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.Approved
ImatinibThe metabolism of Prochlorperazine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Prochlorperazine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.Investigational, Withdrawn
IndenololProchlorperazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Prochlorperazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indiplon.Investigational
Iofetamine I-123Prochlorperazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoniumThe metabolism of Prochlorperazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prochlorperazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Prochlorperazine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Prochlorperazine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Prochlorperazine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prochlorperazine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Prochlorperazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolProchlorperazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.Approved, Investigational
LandiololProchlorperazine may increase the hypotensive activities of Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.Approved, Investigational
LevobunololProchlorperazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.Approved, Investigational
LisdexamfetamineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Prochlorperazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.Approved
LorcaserinThe metabolism of Prochlorperazine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lormetazepam.Approved
LovastatinThe metabolism of Prochlorperazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.Approved
LuliconazoleThe serum concentration of Prochlorperazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Prochlorperazine can be increased when combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Prochlorperazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Prochlorperazine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Prochlorperazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melperone.Approved, Investigational
MephedroneProchlorperazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineProchlorperazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololProchlorperazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meptazinol.Experimental
MequitazineProchlorperazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.Approved
MethadoneThe metabolism of Prochlorperazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineProchlorperazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.Approved
MethotrimeprazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineProchlorperazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.Approved
MetipranololProchlorperazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.Approved, Investigational
MetoprololThe metabolism of Prochlorperazine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineProchlorperazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.Approved, Illicit
MidomafetamineProchlorperazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Prochlorperazine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Prochlorperazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Investigational
MirabegronThe metabolism of Prochlorperazine can be decreased when combined with Mirabegron.Approved
MirtazapineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane.Approved
MizoribineThe serum concentration of Prochlorperazine can be increased when it is combined with Mizoribine.Investigational
MMDAProchlorperazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Investigational
NadololProchlorperazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.Approved, Investigational
NebivololProchlorperazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Prochlorperazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Prochlorperazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Prochlorperazine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.Approved
NicomorphineProchlorperazine may increase the hypotensive activities of Nicomorphine.Experimental
NilotinibThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Prochlorperazine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Opium.Approved, Illicit
OrphenadrineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Prochlorperazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Prochlorperazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Prochlorperazine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololProchlorperazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Prochlorperazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Prochlorperazine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenoxyethanol.Approved
PhentermineProchlorperazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Prochlorperazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.Approved
PindololProchlorperazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pizotifen.Approved
Platelet Activating FactorProchlorperazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Prochlorperazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololProchlorperazine may increase the hypotensive activities of Practolol.Approved
PramipexoleProchlorperazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prochlorperazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Prochlorperazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Prochlorperazine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.Approved
ProguanilThe serum concentration of Prochlorperazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Prochlorperazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propoxycaine.Approved
PropranololProchlorperazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Prochlorperazine is combined with PSD502.Investigational
PseudoephedrineProchlorperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Prochlorperazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Prochlorperazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine.Approved
QuinidineThe metabolism of Prochlorperazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Prochlorperazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Prochlorperazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.Approved, Investigational
RifabutinThe metabolism of Prochlorperazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Prochlorperazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Prochlorperazine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ritanserin.Investigational
RitobegronProchlorperazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Prochlorperazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.Approved
RolapitantThe metabolism of Prochlorperazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Romifidine.Vet Approved
RopiniroleProchlorperazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ropivacaine.Approved
RotigotineProchlorperazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.Approved
SaquinavirThe metabolism of Prochlorperazine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Prochlorperazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Prochlorperazine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prochlorperazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prochlorperazine can be increased when it is combined with Simeprevir.Approved
SinefunginThe serum concentration of Prochlorperazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
SotalolProchlorperazine may increase the hypotensive activities of Sotalol.Approved
St. John's WortThe serum concentration of Prochlorperazine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Prochlorperazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Prochlorperazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Prochlorperazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleThe metabolism of Prochlorperazine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.Approved, Investigational
SuvorexantProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Prochlorperazine can be increased when it is combined with tafenoquine.Investigational
TalinololProchlorperazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.Approved
TelaprevirThe metabolism of Prochlorperazine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Prochlorperazine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.Approved
TerbinafineThe metabolism of Prochlorperazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololProchlorperazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrodotoxin.Investigational
ThalidomideProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Prochlorperazine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Prochlorperazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tilidine.Experimental
TimololProchlorperazine may increase the hypotensive activities of Timolol.Approved
TipranavirThe metabolism of Prochlorperazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Prochlorperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe metabolism of Prochlorperazine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Veralipride.Experimental
VerapamilThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Prochlorperazine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.Approved, Investigational
ZolpidemProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

References

Synthesis Reference
US2902484
General References
Not Available
External Links
Human Metabolome Database
HMDB14577
KEGG Drug
D00493
KEGG Compound
C07403
PubChem Compound
4917
PubChem Substance
46509018
ChemSpider
4748
BindingDB
78434
ChEBI
8435
ChEMBL
CHEMBL728
Therapeutic Targets Database
DAP000373
PharmGKB
PA451114
HET
P77
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prochlorperazine
ATC Codes
N05AB04 — Prochlorperazine
AHFS Codes
  • 56:22.08 — Antihistamines
  • 28:16.08.24 — Phenothiazines
PDB Entries
3m0w
FDA label
Download (617 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMigraines1
2CompletedTreatmentNausea and Vomiting1
2TerminatedTreatmentBenign Headache1
3CompletedSupportive CareNausea1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3RecruitingTreatmentMigraine Disorders1
3TerminatedTreatmentHeadaches1
4CompletedTreatmentHeadaches1
4CompletedTreatmentMigraines2
4RecruitingTreatmentHeadaches1
4TerminatedTreatmentMigrainous Headache1
Not AvailableCompletedTreatmentAcute Migraine Headache1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Paddock laboratories inc
  • Able laboratories inc
  • G and w laboratories inc
  • Alpharma us pharmaceuticals division
  • Morton grove pharmaceuticals inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Cadista pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SuppositoryRectal10 mg
TabletOral10 mg
TabletOral5 mg
SuppositoryRectal25 mg/1
InjectionIntramuscular5 mg/mL
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous5 mg/mL
TabletOral10 mg/1
TabletOral5 mg/61
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
LiquidIntramuscular; Intravenous5 mg
SolutionIntramuscular; Intravenous5 mg
SyrupOral5 mg
Prices
Unit descriptionCostUnit
Prochlorperazine mal powder4.77USD g
Compazine 25 mg suppository4.25USD suppository
Prochlorperazine 25 mg suppository3.13USD suppository
Compro 25 mg suppository3.05USD suppository
Compazine 5 mg tablet1.82USD tablet
Compazine 10 mg tablet1.8USD tablet
Prochlorperazine 5 mg/ml vial1.22USD ml
Prochlorperazine 5 mg/ml0.91USD ml
Prochlorperazine Maleate 10 mg tablet0.88USD tablet
Sandoz Prochlorperazine 10 mg Suppository0.87USD suppository
Prochlorperazine 10 mg tablet0.85USD tablet
Prochlorperazine Maleate 5 mg tablet0.59USD tablet
Prochlorperazine 5 mg tablet0.57USD tablet
Apo-Prochlorazine 10 mg Tablet0.21USD tablet
Apo-Prochlorazine 5 mg Tablet0.17USD tablet
Novamine 15% iv solution0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)228 °CPhysProp
water solubility15 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.88HANSCH,C ET AL. (1995)
logS-4.4ADME Research, USCD
pKa8.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.011 mg/mLALOGPS
logP4.67ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity109.81 m3·mol-1ChemAxon
Polarizability41.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9781
Caco-2 permeable+0.7729
P-glycoprotein substrateSubstrate0.8537
P-glycoprotein inhibitor IInhibitor0.817
P-glycoprotein inhibitor IIInhibitor0.8577
Renal organic cation transporterInhibitor0.7615
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateNon-substrate0.5179
CYP450 3A4 substrateNon-substrate0.5346
CYP450 1A2 substrateInhibitor0.9376
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.9723
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.7676
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.8999
CarcinogenicityNon-carcinogens0.9456
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3496 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8165
hERG inhibition (predictor II)Inhibitor0.786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.4 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01vo-9853000000-ba88fedd94e150c34e1a
GC-MS Spectrum - EI-BGC-MSsplash10-0229-7933000000-4e14a9a9728c361941d3
Mass Spectrum (Electron Ionization)MSsplash10-022c-9752000000-533ac31876b44d82f2aa
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0219000000-abf2f9a1f6a1efb497b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Benzenoids / Aryl chlorides / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-alkylpiperazine / N-methylpiperazine / Para-thiazine / Aryl chloride / Aryl halide
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, organochlorine compound, N-alkylpiperazine, N-methylpiperazine (CHEBI:8435)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Roberge RJ: Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch. J Emerg Med. 2006 Apr;30(3):299-302. [PubMed:16677982]
  3. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092]
  4. Vinson DR: Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. J Emerg Med. 2006 Aug;31(2):139-45. [PubMed:17044574]
  5. Callan JE, Kostic MA, Bachrach EA, Rieg TS: Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5. [PubMed:18534808]
  6. Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol. 2008 Dec 14;600(1-3):105-9. doi: 10.1016/j.ejphar.2008.10.030. Epub 2008 Oct 21. [PubMed:18955042]
  7. Golembiewski J, Tokumaru S: Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. [PubMed:17169748]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34